NSE · FDC.NS
FDC Limited
₹378.95+₹1.80 (+0.48%)
FDC Limited’s quoted price sits in the lower half of its reported 52-week range, 19.99% below the high.
Loading market information…
BSE · FERMENTA.BO · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:54 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Fermenta Biotech Ltd.’s quoted price sits in the upper half of its reported 52-week range, 26.8% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Fermenta Biotech Ltd.’s forward annual dividend is ₹3.75 per share, paid annual. The forward yield is 0.88% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Fermenta Biotech Ltd.’s next earnings report is currently expected on Nov 14, 2026, with estimated earnings per share of ₹3.30. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Fermenta Biotech Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Fermenta Biotech Ltd. primarily focuses on the creation and provision of Vitamin D3. Their extensive range of offerings includes various forms like crystalline, oil, resin in oil, cold water dispersible (CWD) preparations, and feed-grade powder. These adaptable products are utilized across multiple sectors, such as in pharmaceutical injectables, soft gel capsules, premixes, and for enhancing the nutritional value of food and beverages. The company's business activities are structured into two main divisions: the Chemicals/Bulk Drug segment, which involves the production and sale of chemicals, pharmaceutical ingredients, and enzymes; and the Property segment, dedicated to leasing out real estate. Established on May 1, 1951, by Vijay Kumar Raju Datla, the firm maintains its headquarters in Mumbai, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2024 | May 28, 2025 | ₹11.84+258.79% vs estimate | ₹1.40B+22.35% vs estimate |
|---|
| Q3 2024 | Feb 11, 2025 | ₹12.71+408.4% vs estimate | ₹1.56B+82.15% vs estimate |
|---|
| Q2 2024 | Nov 14, 2024 | ₹3.94+19.39% vs estimate | ₹950.28M+47.33% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹378.95+₹1.80 (+0.48%)
FDC Limited’s quoted price sits in the lower half of its reported 52-week range, 19.99% below the high.
₹373.65-₹2.15 (-0.57%)
Gujarat Themis Biosyn Limited’s quoted price sits in the upper half of its reported 52-week range, 20.85% below the high.
₹854.65-₹38.75 (-4.34%)
Orchid Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 25.26% below the high.
₹637.00-₹18.25 (-2.79%)
Solara Active Pharma Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 17.7% below the high.
₹244.40-₹7.60 (-3.02%)
Kopran Limited’s quoted price sits in the upper half of its reported 52-week range, 17.44% below the high.
₹35.91-₹1.04 (-2.81%)
Sudarshan Pharma Industries Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.08% below the high.
₹184.57+₹2.64 (+1.45%)
Wanbury Limited’s quoted price sits in the lower half of its reported 52-week range, 48.57% below the high.
₹110.75-₹0.09 (-0.08%)
Aarey Drugs & Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 3.53% below the high.
